Immunologic Factor
Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up
Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers
Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future
CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation
GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market
Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults
Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders
Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders
Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev
Corbus Pharmaceuticals, CRB-701, antibody-drug conjugate, Nectin-4, urothelial cancer, head and neck cancer, Padcev, clinical trial, ASCO-GU 2025
Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis
Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody
Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment
Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment
Robert F. Kennedy Jr. Confirmed as HHS Secretary in Close Senate Vote
RFK Jr., HHS Secretary, Senate confirmation, Trump administration, vaccine skepticism, healthcare policy, Make America Healthy Again
FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma
Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy
Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails in Phase 3 Trial
E. coli vaccine, Sanofi, Johnson & Johnson, Phase 3 trial failure, invasive E. coli disease, ExPEC9V